Interní Med. 2005; 7(9): 384-386

News in the treatment of diabetic nephropaty

doc. MUDr. Vladimír Tesař DrSc
I. interní klinika 1. LF UK a VFN Praha

Diabetic nephropathy is the most frequent cause of end-stage renal failure in developed countries and its prevalence is steadily increasing. Patients with diabetic nephropathy are, however, endangered more by their high cardiovascular mortality than by the development of end-stage renal failure. Treatment of hypertension with the target blood pressure lower than 130/85 mm Hg lowers in patients with diabetic nephropathy not only cardiovascular risk, but also the risk of progression of the renal disease. While the renoprotective effect of the angiotensin converting enzyme inhibitors and angiotensin antagonists is well documented, evidence for their higher cardioprotectivity compared to other classes of antihypertensive drugs is rather controversial.

Keywords: Key words: diabetic nephropathy, microalbuminuria, ACE inhibitors, angiotensin antagonists, dyslipidemia.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tesař V. News in the treatment of diabetic nephropaty. Interní Med. 2005;7(9):384-386.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. American Diabetes Association: Management of dyslipidemia in adults with diabetes. Diabetes Care, 2003, 26 (Suppl. 1): S83-S86. Go to original source... Go to PubMed...
    2. Andersen NH, Poulsen PL, Knudsen ST, et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care, 2005; 28: 273-277. Go to original source... Go to PubMed...
    3. Bakris GL, et al. Effects of blood pressure level on progression of diabetic nephropathy. Arch Intern Med 2003; 163: 1555-1565. Go to original source... Go to PubMed...
    4. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N. Engl J. Med., 2004; 351: 1952-1961. Go to original source... Go to PubMed...
    5. Berl T, et al. Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003; 138: 542-549. Go to original source... Go to PubMed...
    6. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med., 2001; 345: 861-869. Go to original source... Go to PubMed...
    7. Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch. Intern. Med., 2001; 161: 1207-1216. Go to original source... Go to PubMed...
    8. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001; 285: 2486-2497. Go to original source... Go to PubMed...
    9. Guidelines Committee: 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 2003; 21: 1011-1053. Go to original source... Go to PubMed...
    10. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA, 2003; 289: 2560-2572. Go to original source... Go to PubMed...
    11. Laverman GD, Remuzzi G, Ruggenenti P. ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection? J. Am. Soc. Nephrol., 2004; 15 (Suppl. 1): S64-S70. Go to original source... Go to PubMed...
    12. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N. Engl. J. Med., 1993; 329: 1456-1462. Go to original source... Go to PubMed...
    13. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med., 2001; 34: 851-860. Go to original source... Go to PubMed...
    14. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet, 2003; 361: 117-124. Go to original source... Go to PubMed...
    15. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med., 2001; 345: 870-878. Go to original source... Go to PubMed...
    16. Quaschning T, Wanner C. Dyslipidemia and renal disease: pathogenesis and clinical consequences. Curr. Opin. Nephrol. Hypertens., 2001; 10: 195-201. Go to original source... Go to PubMed...
    17. Ruggenenti P, Fassi A, Parvano Ilieva A, et al. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med., 2004; 351: 1941-1951. Go to original source... Go to PubMed...
    18. Rychlík I, Miltenberger-Miltenyi G, Ritz E. The drama of the continuous increase in end-stage renal failure in patients with type II diabetes mellitus. Nephrol. Dial. Transplant., 1998; 13 (Suppl. 8): 6-10. Go to original source... Go to PubMed...
    19. Schwenger V, Ritz E. Audit of antihypertensive treatment in patients with renal failure. Nephrol. Dial. Transplant., 1998; 13: 3091-3095. Go to original source... Go to PubMed...
    20. Tonelli M, Moyé L, Sacks FM, et al. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J. Am. Soc. Nephrol., 2003; 14: 1605-1613. Go to original source... Go to PubMed...
    21. Villarosa IP, Bakris GL. Antihypertensive therapy in type 2 diabetes with nephropathy. In: Ritz E, Rychlík I. Nephropathy in type 2 diabetes. Oxford University Press, Oxford, 1999; 111-136. Go to original source...
    22. Wanner C, Krane V, Marz W, et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res., 2004; 27: 259-266. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.